{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-010062","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2022-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.750064+00:00","generated_at":"2026-06-25T01:23:33.993438+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Xilio Therapeutics promotes Martin Huber to President; appoints Robert Ross to Board","bullets":["Martin Huber promoted to President, continues as head of R&D; new employment agreement with $500k base salary and 50% target bonus.","Huber granted option to purchase 20,000 shares of common stock, vesting over 4 years in equal monthly installments.","Robert Ross, M.D., appointed to Board as Class II director effective June 15, 2022; also joins Compensation Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-010062","json":"https://secwatch.observer/filing/0001558370-22-010062.json","markdown":"https://secwatch.observer/filing/0001558370-22-010062.md","text":"https://secwatch.observer/filing/0001558370-22-010062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022010062/0001558370-22-010062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022010062/xlo-20220615x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T01:23:33.993438+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2079fb998a","claim":"Robert Ross was appointed as Class II director at Xilio Therapeutics, Inc..","evidence_excerpt":"Effective June 15, 2022, the Board, on the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Robert Ross, M.D. to the Board as a Class II director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022010062/0001558370-22-010062-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"},{"claim_id":"e5382272d6","claim":"Martin Huber changed role as President at Xilio Therapeutics, Inc..","evidence_excerpt":"On June 15, 2022, the Board of Directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”) promoted Martin Huber, M.D., 62, to President of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022010062/0001558370-22-010062-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}